New strategy to target transcription factor STAT5 to combat leukaemia

(University of Veterinary Medicine -- Vienna) Acute myeloid leukaemia is the most common type of acute cancer of the blood and bone marrow in adults. AML progresses quickly and only 26 percent of the patients survive longer than 5 years as resistance against established treatments arises. The most common molecular cause is FLT3 mutations, which result in hyper-activation of STAT5. A researcher consortium now reports on an early preclinical development to target STAT5 directly, which cooperates well with existing therapies.
Source: EurekAlert! - Biology - Category: Biology Source Type: news